IP Library Granted Patent US 9,248,197
Granted Patent B2
US 9,248,197 · App. 14/312,748 · Granted Feb 2, 2016

Activation of polysaccharides via the cyanylating agent, 1-cyanoimidazole (1-Cl), in the preparation of polysaccharide/protein conjugate vaccines

Inventor: Andrew Lees (Silver Spring, MD)
Assignee: Fina BioSolutions, LLC
A61K47/4823A61K39/00A61K39/095A61K39/145A61K47/48284C08B37/006C08B37/0021C08H1/00A61K2039/6087A61K2039/627
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,248,197
App. No.
14/312,748
Granted
Feb 2, 2016
Kind
B2
Abstract

This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.

Claims (10)

1. A process of conjugation of a carbohydrate comprising:

mixing 1-cyanoimidazole (1-CI) with the carbohydrate to create an activated chemical compound; and

mixing the activated compound with an antigenic second compound to create a conjugate, wherein the second compound is a peptide, a polypeptide or a protein.

2. The process of claim 1 , wherein the carbohydrate is a natural or synthetic carbohydrate, polysaccharide, oligosaccharide, or combination thereof.

3. The process of claim 1 , wherein conjugation is direct or indirect with the addition of functional groups that facilitate conjugation.

4. The process of claim 1 , further comprising removing components with a lower molecular weight than the conjugate by dialysis, filtration, chromatography, or a combination thereof.

5. The process of claim 1 , wherein the conjugate is a vaccine or a diagnostic agent.

6. The process of claim 1 , wherein the steps are performed together.

7. The process of claim 1 , further comprising mixing the activated compound with hexanediamine, ethylenediamine, hydrazine, adipic dihydrazide, or 1,6-diaminooxyhexane to form a linking group between the activated compound and the antigenic second compound.

8. A vaccine or diagnostic agent produced by the process of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2021
From: FINA BIOSOLUTIONS, LLC
To: SERUM INSTITUTE OF INDIA PVT. LTD.
Reel/Frame 057208/0921 →
Continuity (3)
Continuation 13514356
Provisional Application 61287593 · Dec 17, 2009
Related Publication 20140316110A1 · Oct 23, 2014